Bright Minds Biosciences ... (DRUG)
Bright Minds Biosciences Statistics
Share Statistics
Bright Minds Biosciences has - shares outstanding. The number of shares has increased by 60.85% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | 60.85% |
| Shares Change (QoQ) | 55.66% |
| Owned by Institutions (%) | 4.29% |
| Shares Floating | 4.9M |
| Failed to Deliver (FTD) Shares | 308 |
| FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 221.22K, so 3.17% of the outstanding shares have been sold short.
| Short Interest | 221.22K |
| Short % of Shares Out | 3.17% |
| Short % of Float | 4.38% |
| Short Ratio (days to cover) | 1.24 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -20.2. Bright Minds Biosciences's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -20.2 |
| PS Ratio | 0 |
| Forward PS | 4.9 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bright Minds Biosciences Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.32, with a Debt / Equity ratio of 0.02.
| Current Ratio | 11.32 |
| Quick Ratio | 11.32 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.1 |
| Cash Flow / Debt | -15.55 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is -46.27%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | -46.27% |
| Revenue Per Employee | $undefined |
| Profits Per Employee | $undefined |
| Employee Count | undefined |
| Asset Turnover | null |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 2015.91% in the last 52 weeks. The beta is 0.49, so Bright Minds Biosciences's price volatility has been higher than the market average.
| Beta | 0.49 |
| 52-Week Price Change | 2015.91% |
| 50-Day Moving Average | 37.61 |
| 200-Day Moving Average | 19.09 |
| Relative Strength Index (RSI) | 49.43 |
| Average Volume (20 Days) | 91.71K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -2.62M |
| Net Income | -2.8M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.65 |
Balance Sheet
The company has 5.72M in cash and 118.96K in debt, giving a net cash position of 5.6M.
| Cash & Cash Equivalents | 5.72M |
| Total Debt | 118.96K |
| Net Cash | 5.6M |
| Retained Earnings | -34.35M |
| Total Assets | 58.4M |
| Working Capital | 57.76M |
Cash Flow
In the last 12 months, operating cash flow was -1.85M and capital expenditures 0, giving a free cash flow of -1.85M.
| Operating Cash Flow | -1.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.85M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRUG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.75% |
| FCF Yield | -0.71% |
Analyst Forecast
The average price target for DRUG is $85, which is 128.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $85 |
| Price Target Difference | 128.2% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jul 14, 2023. It was a backward split with a ratio of 1:5.
| Last Split Date | Jul 14, 2023 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 249.17 |
| Piotroski F-Score | 1 |